Chemfab Alkalis Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹76 Cr −1.2% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
CA

Chemfab Alkalis Ltd

Q1 FY27Chemicals & Petrochemicals

Chemfab Alkalis Q1 FY27: Revenue ₹73.16 Cr, PAT ₹7.51 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹73Cr
−20.1% YoY
−2.2% QoQ
Net profit
₹6Cr
+124.7% YoY
+1093.8% QoQ
Margin
13.85%
+1.5 pp YoY
+2.5 pp QoQ

Based on Chemfab Alkalis Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹353
Market cap₹531 Cr

The short version

Consolidated Q1FY27 Revenue from Operations: ₹73.16 crore, down 20.08% YoY (from ₹91.54 crore in Q1FY26). Quarterly EBITDA (Q1FY27, Consolidated): ₹10.13 crore - Year-on-year (Y-o-Y) change: -10.35% (from ₹11.30 crore in Q1FY26) - Operating EBITDA margin: 13.85% (up 150 bps Y-o-Y from 12.34%)

From Chemfab Alkalis Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Consolidated Q1FY27 Revenue from Operations: ₹73.16 crore, down 20.08% YoY (from ₹91.54 crore in Q1FY26). (Page 7)
  • Chemical Segment Q1FY27 Revenue: ₹67.41 crore, up 27.57% YoY (from ₹52.84 crore in Q1FY26). (Page 8)
  • OPVC Segment Q1FY27 Revenue: ₹5.75 crore, down 85.14% YoY (from ₹38.70 crore in Q1FY26). (Page 9)
  • ECU Realisations in Chlor-Alkali: Improved sequentially to ₹39,600/MT from ₹39,100/MT in Q4FY26 (Page 6, Page 5)

2 more points from Chemfab Alkalis Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Chemfab Alkalis Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Chlor-Alkali business:
  • ₹56 crore invested in technology modernisation to improve power efficiency by July 2025 (completed Q3FY26).
  • ₹15 crore invested in a 10 MW hybrid power project reducing power cost; supply started Q1 FY27 (operational from 25th May 2026).
  • OPVC Pipes Business capacity expansion at Sri City:
  • Scaling from 14,000 TPA (FY25) to 20,000 TPA (FY26) with new production lines.
  • Additional lines planned: 5th line (Q2FY26, ₹27 crore), 6th line (Q3FY26, ₹28 crore), 7th line (Q2FY27, ₹30 crore).
  • Total capex for lines 5-7 approximately ₹85 crore.
  • Each line capacity: 2,500-3,000 TPA; payback ~2–2.5 years.

2 more points from Chemfab Alkalis Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Chemfab Alkalis Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Chemfab Alkalis Ltd said on order book & pipeline — free account, 30 seconds.

Chemfab Alkalis Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Chemfab Alkalis Ltd Q1 FY27 results — key figures

Chemfab Alkalis Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue7392-20.1%75-2.2%
Operating profit (EBITDA)1011-10.4%9+18.9%
Operating margin13.85%12.34%+1.5 pp11.39%+2.5 pp
Profit before tax25-52.8%1+80.5%
Net profit (PAT)63+124.7%0+1093.8%
EPS (₹)3.991.78+124.2%0.33+1109.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹76 Cr, net loss ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Alufluoride (Q1 FY27)

    Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr

  • POCL Enterprises (Q1 FY27)

    466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto

  • Devson Catalyst (Q1 FY27)

    FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee

  • Ambani Orgochem (Q1 FY27)

    Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Chemfab Alkalis Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Chemfab Alkalis Ltd Q1 FY27 results?

Consolidated Q1FY27 Revenue from Operations: ₹73.16 crore, down 20.08% YoY (from ₹91.54 crore in Q1FY26). Quarterly EBITDA (Q1FY27, Consolidated): ₹10.13 crore - Year-on-year (Y-o-Y) change: -10.35% (from ₹11.30 crore in Q1FY26) - Operating EBITDA margin: 13.85% (up 150 bps Y-o-Y from 12.34%)

What is Chemfab Alkalis Ltd share price analysis?

Chemfab Alkalis Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹531 Cr. Investors should review the full earnings analysis for detailed insights.

Is Chemfab Alkalis Ltd planning capital expenditure?

Chlor-Alkali business: - ₹56 crore invested in technology modernisation to improve power efficiency by July 2025 (completed Q3FY26).

Keep Chemfab Alkalis Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.